Validea's guru fundamental report rates Becton Dickinson and Co (BDX), a large-cap medical equipment stock, at 54% using its Peter Lynch-based P/E/Growth Investor model. While this is BDX's highest rating among Validea's strategies, the 54% score falls significantly below the 80-90% threshold typically signaling investment interest. This moderate rating is attributed to BDX failing criteria for Sales and P/E Ratio and EPS Growth Rate, despite passing tests for P/E/Growth Ratio, Inventory to Sales, and Total Debt/Equity, with Free Cash Flow and Net Cash Position noted as neutral.
Becton Dickinson and Co. (BDX) presents a mixed fundamental profile according to Validea's P/E/Growth Investor model, which is based on Peter Lynch's strategy. The company scores a 54%, a rating that falls significantly below the 80% threshold typically indicating model interest. This lukewarm assessment, reflected in a mildly negative sentiment score of -0.3, stems from a failure to meet crucial growth-related criteria. Specifically, BDX fails on its EPS Growth Rate and its Sales and P/E Ratio, suggesting that its growth trajectory is insufficient to justify its current valuation under this framework. On the positive side, the analysis indicates a strong balance sheet, with BDX passing tests for its Total Debt/Equity ratio and its P/E/Growth (PEG) ratio. Effective inventory management is also a noted strength. However, factors such as Free Cash Flow and Net Cash Position are rated as neutral, providing no strong conviction either way. The overall picture is of a large-cap medical equipment company with solid financial health and inventory control but lacking the core earnings and sales momentum required by a classic growth-at-a-reasonable-price (GARP) strategy.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
